Boehringer Mannheim Corporation Completes Patient Entry for Phase III Trial Program in Hepatitis C

INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the U.S.A. only

Boehringer Ingelheim today announced that the final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335, its investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).

Back to news